title: Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
abstract: Risk-factors for bloodstream infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli were investigated using an exploratory case-double control study in which 43 cases (70% producing CTX-M enzymes) were compared with: (i) 86 patients with bacteraemia caused by non-ESBL-producing E. coli; and (ii) 86 hospitalised patients. Previous follow-up as an outpatient, urinary catheterisation and use of oxyimino-beta-lactams or fluoroquinolones were independent risk-factors for ESBL-producing E. coli among patients with E. coli bacteraemia, and previous use of oxyimino-beta-lactams or fluoroquinolones were also independent risk-factors among hospitalised patients. These findings may help in identifying patients at greater risk for bloodstream infection caused by ESBL-producing E. coli in endemic areas.
authors.affiliation: Sección de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Unviersitario Virgen Macarena, and Departamento de Medicina, Universidad de Sevilla, Sevilla, Spain. jrb@nacom.es
authors.forename: J
authors.initials: J
authors.lastname: Rodríguez-Baño
authors.forename: M D
authors.initials: MD
authors.lastname: Navarro
authors.forename: L
authors.initials: L
authors.lastname: Romero
authors.forename: M A
authors.initials: MA
authors.lastname: Muniain
authors.forename: M de
authors.initials: Md
authors.lastname: Cueto
authors.forename: J
authors.initials: J
authors.lastname: Gálvez
authors.forename: E J
authors.initials: EJ
authors.lastname: Perea
authors.forename: A
authors.initials: A
authors.lastname: Pascual
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D016470:Bacteremia / Q000382:microbiology* / Q000517:prevention & control*; D016022:Case-Control Studies; D004926:Escherichia coli / Q000201:enzymology*; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology*; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010865:Pilot Projects; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D001618:beta-Lactamases / Q000096:biosynthesis*; D047090:beta-Lactams / Q000008:administration & dosage
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D047090:beta-Lactams; D001618:beta-Lactamases